Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1373 ARTÍCULOS , VIENDO DEL 751 AL 765

The mini-Kingston Standardized Cognitive Assessment

Hopkins RW, Kilik LA.

Am J Alzheimers Dis Other Demen. 2013 May;28(3):239-44. doi: 10.1177/1533317513481095. Epub 2013 Mar 28.

Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia

Declercq T, Petrovic M, Azermai M, Vander Stichele R, De Sutter AI, van Driel ML, Christiaens T.

Cochrane Database Syst Rev. 2013 Mar 28;(3):CD007726. doi: 10.1002/14651858.CD007726.pub2.

The Mental Activity and eXercise (MAX) trial: a randomized controlled trial to enhance cognitive function in older adults

Barnes DE, Santos-Modesitt W, Poelke G, Kramer AF, Castro C, Middleton LE, Yaffe K.

JAMA Intern Med. 2013 May 13;173(9):797-804. doi: 10.1001/jamainternmed.2013.189.

Spongiform encephalopathy in siblings with no evidence of protease-resistant prion protein or a mutation in the prion protein gene

Varges D, Schulz-Schaeffer WJ, Wemheuer WM, Damman I, Schmitz M, Cramm M, Kallenberg K, Shirneshan K, Elkenani M, Markwort S, Faist M, Kohlhase J, Windl O, Zerr I.

J Neurol. 2013 Jul;260(7):1871-9. doi: 10.1007/s00415-013-6897-z. Epub 2013 Apr 2.

Predicting cognitive decline: a dementia risk score vs. the Framingham vascular risk scores

Kaffashian S, Dugravot A, Elbaz A, Shipley MJ, Sabia S, Kivimäki M, Singh-Manoux A.

Neurology. 2013 Apr 2;80(14):1300-6. doi: 10.1212/WNL.0b013e31828ab370.

Measurement of aggressive behaviors in dementia: comparison of the physical aggression subscales of the Cohen-Mansfield Agitation Inventory and the Ryden Aggression Scale

Whall AL, Kim H, Colling KB, Hong GR, DeCicco B, Antonakos C.

Res Gerontol Nurs. 2013 Jul;6(3):171-7. doi: 10.3928/19404921-20130321-01. Epub 2013 Mar 28.

Risk factors for β-amyloid deposition in healthy aging: vascular and genetic effects

Rodrigue KM, Rieck JR, Kennedy KM, Devous MD Sr, Diaz-Arrastia R, Park DC.

JAMA Neurol. 2013 May;70(5):600-6. doi: 10.1001/jamaneurol.2013.1342.

Test Your Memory (TYM) as a screening instrument in clinical practice - the Polish validation study

Szczesniak D, Wojtynska R, Rymaszewska J.

Aging Ment Health. 2013;17(7):863-8. doi: 10.1080/13607863.2013.784957. Epub 2013 Apr 5.

Nonpharmacologic treatment and prevention strategies for dementia

Yaffe K, Hoang T.

Continuum (Minneap Minn). 2013 Apr;19(2 Dementia):372-81. doi: 10.1212/01.CON.0000429178.14354.67.

Incorporating new diagnostic schemas, genetics, and proteinopathy into the evaluation of frontotemporal degeneration

Chow TW, Alobaidy AA.

Continuum (Minneap Minn). 2013 Apr;19(2 Dementia):438-56. doi: 10.1212/01.CON.0000429173.35439.9c.

"Will I get Alzheimer disease?" when cognitively normal patients ask to be tested for Alzheimer disease

Snider BJ, Buckles VD.

Continuum (Minneap Minn). 2013 Apr;19(2 Dementia):470-4. doi: 10.1212/01.CON.0000429171.50686.07.

Genetic testing for early-onset Alzheimer disease

Tsao JW.

Continuum (Minneap Minn). 2013 Apr;19(2 Dementia):475-9. doi: 10.1212/01.CON.0000429170.50686.4e.

Patient management problem

Pierce A.

Continuum (Minneap Minn). 2013 Apr;19(2 Dementia):519-37. doi: 10.1212/01.CON.0000429166.97320.81.

Under-provision of medical care for vascular diseases for people with dementia in primary care: a cross-sectional review

Connolly A, Campbell S, Gaehl E, Iliffe S, Drake R, Morris J, Martin H, Purandare N.

Br J Gen Pract. 2013 Feb;63(607):e88-96. doi: 10.3399/bjgp13X663046.

Predictors of progression from mild cognitive impairment to dementia in the placebo-arm of a clinical trial population

Prins ND, van der Flier WM, Brashear HR, Knol DL, van de Pol LA, Barkhof F, Scheltens P.

J Alzheimers Dis. 2013;36(1):79-85. doi: 10.3233/JAD-122233.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias